공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

프로스타글란딘 E2 수용체 EP4 아류형(프로스타노이드 EP4 수용체, PTGER4) : 파이프라인 리뷰

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 363568
페이지 정보 영문 80 Pages
가격
US $ 3,500 ₩ 4,191,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,000 ₩ 8,382,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,500 ₩ 12,573,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


프로스타글란딘 E2 수용체 EP4 아류형(프로스타노이드 EP4 수용체, PTGER4) : 파이프라인 리뷰 Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 80 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 각국에서의 프로스타글란딘 E2 수용체 EP4 아류형(프로스타노이드 EP4 수용체, PTGER4) 치료제 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발 및 출시 최신 동향, 임상시험 각 단계의 제품 목록, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

목차

  • 서론
    • 분석 범위
  • 프로스타글란딘 E2 수용체 EP4 아류형(프로스타노이드 EP4 수용체, PTGER4) 개요
  • 치료제 개발 상황
    • 임상시험 단계별
    • 치료 분야별
    • 증상별
  • 파이프라인 제품 개요
    • 후기 단계 제품
    • 초기 단계 제품
  • 각 기업에서 개발중인 치료제
  • 각 대학 및 연구기관에서 개발중인 치료제
  • 치료제 평가
    • 단독치료 제품/병용 제품별
    • 작용기서별
    • 투여 방법별
    • 분자 종류별
  • 치료제 개발에 참여하고 있는 기업
    • AskAt Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • aken Pharmaceutical Co., Ltd.
    • Ono Pharmaceutical Co., Ltd.
  • 약제 개요
    • AAT-008
      • 제품 개요
      • 작용기서
      • 연구 개발(R&D) 진전 상황
    • CR-6086
    • E-7046
    • ER-886046
    • grapiprant
    • KAG-308
    • ONO-4232
    • P-001
    • Small Molecule to Antagonize EP4 Receptor for Inflammatory Pain
    • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis
  • 개발이 휴지 상태인 제품
  • 개발이 중지된 제품
  • 주목해야 할 최신 동향 및 프레스 릴리스(1건)
  • 부록

도표

KSM 16.08.04

List of Tables

List of Tables

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Indications, 2021 (Contd..1)
  • Number of Products under Development by Indications, 2021 (Contd..2)
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Companies, 2021 (Contd..4)
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by AskAt Inc, 2021
  • Pipeline by Domain Therapeutics SA, 2021
  • Pipeline by Eisai Co Ltd, 2021
  • Pipeline by Exalys Therapeutics Inc, 2021
  • Pipeline by GlaxoSmithKline Plc, 2021
  • Pipeline by Gurus BioPharm, 2021
  • Pipeline by Kaken Pharmaceutical Co Ltd, 2021
  • Pipeline by Kanaph Therapeutics Inc, 2021
  • Pipeline by Medibiofarma SL, 2021
  • Pipeline by Mesentech Inc, 2021
  • Pipeline by NB Health Laboratory Co Ltd, 2021
  • Pipeline by Ono Pharmaceutical Co Ltd, 2021
  • Pipeline by RaQualia Pharma Inc, 2021
  • Pipeline by Rottapharm Biotech Srl, 2021
  • Pipeline by Shanghai Bioray Laboratory Inc, 2021
  • Pipeline by Sosei Group Corp, 2021
  • Pipeline by TempestTx, Inc., 2021
  • Pipeline by Teon Therapeutics Inc, 2021
  • Dormant Products, 2021
  • Dormant Products, 2021 (Contd..1)
  • Discontinued Products, 2021
  • Discontinued Products, 2021 (Contd..1)

List of Figures

List of Figures

  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Mechanism of Actions, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) pipeline Target constitutes close to 21 molecules. Out of which approximately 20 molecules are developed by companies and remaining by the universities/institutes. The latest report Prostaglandin E2 Receptor EP4 Subtype - Drugs In Development, 2021, outlays comprehensive information on the Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Prostaglandin E2 receptor 4 (EP4) is a prostaglandin receptor encoded by the PTGER4 gene. The activity of the receptor is mediated by G proteins that stimulate adenylate cyclase. It has a relaxing effect on smooth muscle. It plays an important role in regulating renal hemodynamics, intestinal epithelial transport, adrenal aldosterone secretion, and uterine function. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 13 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Immunology, Musculoskeletal Disorders, Respiratory, Women's Health, Gastrointestinal, Genetic Disorders and Undisclosed which include indications Colorectal Cancer, Gastric Cancer, Solid Tumor, Autoimmune Disorders, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Rectal Cancer, Triple-Negative Breast Cancer (TNBC), Chronic Obstructive Pulmonary Disease (COPD), Endometriosis, Head And Neck Cancer Squamous Cell Carcinoma, Lung Cancer, Osteoarthritis, Pain, Allergies, Asthma, Bladder Cancer, Bone Defects, Breast Cancer, Cervical Cancer, Colon Cancer, Delirium, Esophageal Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Inflammatory Bowel Disease, Inflammatory Pain, Liver Cancer, Lung Adenocarcinoma, Melanoma, Metastatic Pancreatic Cancer, Muscle Invasive Bladder Cancer (MIBC), Neuroinflammation, Osteoarthritis Pain, Osteogenesis Imperfecta, Osteoporosis, Pancreatic Cancer, Pneumonia, Prostate Cancer, Renal Cell Carcinoma, Rheumatoid Arthritis, Sarcomas, Squamous Non-Small Cell Lung Cancer, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified and Unspecified Cancer.

Furthermore, this report also reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)
  • The report reviews Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Overview
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Companies Involved in Therapeutics Development
  • AskAt Inc
  • Domain Therapeutics SA
  • Eisai Co Ltd
  • Exalys Therapeutics Inc
  • GlaxoSmithKline Plc
  • Gurus BioPharm
  • Kaken Pharmaceutical Co Ltd
  • Kanaph Therapeutics Inc
  • Medibiofarma SL
  • Mesentech Inc
  • NB Health Laboratory Co Ltd
  • Ono Pharmaceutical Co Ltd
  • RaQualia Pharma Inc
  • Rottapharm Biotech Srl
  • Shanghai Bioray Laboratory Inc
  • Sosei Group Corp
  • TempestTx, Inc.
  • Teon Therapeutics Inc
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Drug Profiles
  • AAT-008 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BYD-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CR-6086 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Drugs to Antagonize EP4 for Delirium and NeuroInflammation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • DT-095895 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • grapiprant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GSK-726701A - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • GUR-501 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KAG-308 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KNP-502 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MBF-251 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MES-1007 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MES-1088 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ONO-4578 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • P-001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • palupiprant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize EP4 for Unspecified Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Target Prostanoid EP4 Receptor for Inflammatory Bowel Disease - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TPST-1495 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TT-038 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Dormant Products
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Discontinued Products
  • Prostaglandin E2 Receptor EP4 Subtype (Prostanoid EP4 Receptor or PTGER4) - Product Development Milestones
  • Featured News & Press Releases
  • Aug 24, 2020: Adlai Nortye announces first patient dosed in phase 1b clinical trial of AN0025 (EP4 Antagonist) in combination with Merck's KEYTRUDA (pembrolizumab) for advanced solid tumors
  • Jan 30, 2020: Tempest Therapeutics announces FDA clearance of investigational new drug application for TPST-1495 and welcomes new investors
  • Sep 30, 2019: Adlai Nortye presents encouraging phase 1b study data of AN0025 (an Oral EP4 Antagonist) for locally advanced rectal cancer at ESMO 2019
  • May 07, 2019: Kyn Therapeutics strengthens leadership team with key appointments
  • Dec 20, 2018: Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
  • Jul 19, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Is Approved in China
  • Apr 17, 2018: Japan Patent Office Granted AskAt a Cartilage Disease Use Patent of EP4 Antagonist
  • Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
  • Jan 22, 2018: Investigational New Drug (IND) Application for EP4 antagonist AAT-007 for Oncology Filed in China
  • Dec 18, 2017: Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China
  • Sep 01, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Korea
  • Sep 01, 2017: Eisai to Present Abstract on E7046 at ESMO 2017 Congress
  • Sep 01, 2017: Eisai to Present Abstract on its Oncology Product Candidate E7046 at the ESMO 2017 Congress
  • Jun 30, 2017: India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)
  • Apr 25, 2017: Autoimmune disease Use Patent for EP4 antagonist Approved in Japan
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q